Ensign Peak Advisors
NAUT icon

Ensign Peak Advisors’s Nautilus Biotechnolgy NAUT Stock Holding History

Ensign Peak Advisors’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-134,695
Closed -$585K – 2188
2022
Q1 		$585K Hold
134,695
– – ﹤0.01% 1481
2021
Q4 		$698K Buy
+134,695
New +$721K ﹤0.01% 1465

Other funds holding NAUT

AEPBI
AH Equity Partners Bio II Menlo Park, California $144M AUM 54.61% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Ensign Peak Advisors's NAUT Position: Q2 2022 in Review

Ensign Peak Advisors sold out of Nautilus Biotechnolgy (NAUT) in Q2 2022, closing a stake of 134,695 shares — an estimated $585K sold.

Ensign Peak Advisors first reported a position in NAUT in Q4 2021 and held it in 2 quarters. The position peaked at $698K in Q4 2021. 83 funds tracked by Wall St. Rank hold NAUT as of Q2 2022.

  • Ensign Peak Advisors reported no remaining Nautilus Biotechnolgy position as of Q2 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 134,695 Nautilus Biotechnolgy shares in Q2 2022, an estimated $585K.
  • Ensign Peak Advisors first reported a position in Nautilus Biotechnolgy in Q4 2021 and held it in 2 quarters.
  • Ensign Peak Advisors's Nautilus Biotechnolgy position peaked at $698K in Q4 2021.
  • 83 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2022.

Based on Ensign Peak Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.